Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
129Xe MRI/MRS to Monitor Sotatercept Response in PAH
NCT06351345Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hyperpolarized xenon gas in pulmonary arterial hypertension (PAH). Primary endpoints: Change in Xenon MRI Red Blood Cell (RBC) percentage at 12 months and Change in cardiogenic oscillation amplitudes at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06351345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351345.